Geneoscopy Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding U.S. Patent No. 11,634,781 (“the ‘781 patent”) and U.S. Patent No. 11,970,746 (“the ‘746 patent”).
Exact Sciences’ preliminary injunction motion, filed in July 2024, sought to prevent Geneoscopy’s commercialization of its stool-based colorectal cancer screening test, ColoSense. The withdrawal is consistent with Geneoscopy’s firmly held view that the preliminary injunction motion was baseless. This development allows Geneoscopy to continue expanding access to ColoSense for eligible patients and providers without restriction.
“By taking this step, Exact Sciences confirms what we have said all along—ColoSense is grounded in innovation, not infringement,” said Andrew Barnell, co-founder and CEO of Geneoscopy. “Competition fosters scientific progress and improves patient care. We are excited to continue moving ColoSense forward, bringing a new and patient-friendly cancer screening option to market that enhances early detection and saves lives.”
Withdrawal of the preliminary injunction motion follows other recent favorable developments for Geneoscopy. In July, the U.S. Patent Trial and Appeal Board (PTAB) found all 20 challenged claims of the ’781 patent unpatentable. This was preceded by PTAB’s decision to institute review of a second patent asserted by Exact Sciences (the ‘746 patent) on substantially the same grounds cited by the PTAB in invalidating the ‘781 patent.
Read Also: eClinical Solutions Announces Integrated Data Review Plan (IDRP) Capabilities Within elluminate Platform
